Non Invasive Imaging Methods for Detecting PA:a Clinical PET Study of 18F-Pentixather
Non Invasive Imaging Methods for Detecting Primary Aldosteronism: a Clinical Positron EmissionTomography (PET) Study of 18F-Pentixather
Fangfang Sun
20 participants
Jun 12, 2024
INTERVENTIONAL
Conditions
Summary
Primary aldosteronism (PA) is the most common endocrine cause of hypertension. 68Ga-pentixafor PET/CT possesses a relatively high sensitivity and specificity for Aldosterone producing adenoma (APA) detection. However, 68Ga is usually eluted from a 68Ge-68Ga generator, only a small amount of isotopes can be achieved once time. \[18F\]AlF-chelation is a promising strategy that would solve these issues. 18F labeled Pentixafor-Based Imaging Agent(\[18F\]AlF-NOTA-Pentixather) has been reported by Andreas Poschenrieder. \[18F\]AlF-NOTA-Pentixather displayed high and CXCR4-specific in vivo uptake in Daudi xenografts (13.9%±0.8% injected dose per gram \[ID/g\] at 1 hour post injection\[p.i.\]). But to date 18F-Pentixather has not been studied in humans. In this program the investigators will estimate the radiation dosimetry of \[18F\]AlF-NOTA-Pentixather, evaluate the sensitivity and specificity of the \[18F\]AlF-NOTA-Pentixather as a probe for APA.
Eligibility
Inclusion Criteria3
- Patients diagnosed with primary aldosteronism and willing to undergo surgery
- Clinically highly suspected of primary aldosteronism, but the diagnostic test cannot clearly identify the patients
- Postoperative recurrence in patients with primary aldosteronism
Exclusion Criteria3
- Pregnant and lactating women.
- Patients with poor autonomous behavior ability, severe claustrophobia, and critically ill patients requiring life support who are unable to cooperate in completing the examination.
- There are other situations where patients are not suitable for this examination
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
inject 185\~370MBq \[18F\]AlF-NOTA-Pentixather
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06581744